

BIOMARIN PHARMACEUTICAL INC

Form 4

June 03, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BAFFI ROBERT

(Last) (First) (Middle)

C/O BIOMARIN
PHARMACEUTICAL INC., 105
DIGITAL DRIVE

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL
INC [BMRN]

3. Date of Earliest Transaction
(Month/Day/Year)
05/30/2008

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
SVP, Technical Operations

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	Price			
Common Stock	04/30/2008 ⁽¹⁾		P	V	1,754	A \$ 10.37	36,434	D	
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	M		11,528	A \$ 22	47,962	D	
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S		300	D \$ 38.29	47,662	D	
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S		300	D \$ 38.3	47,362	D	
	05/30/2008 ⁽²⁾	05/30/2008	S		200	D \$ 38.31	47,162	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	2	D	\$ 38.32	47,160	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	500	D	\$ 38.34	46,660	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	500	D	\$ 38.35	46,160	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	100	D	\$ 38.36	46,060	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	100	D	\$ 38.37	45,960	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	598	D	\$ 38.38	45,362	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	200	D	\$ 38.39	45,162	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	100	D	\$ 38.41	45,062	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	1,100	D	\$ 38.42	43,962	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	200	D	\$ 38.43	43,762	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	600	D	\$ 38.44	43,162	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	400	D	\$ 38.45	42,762	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	200	D	\$ 38.46	42,562	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	1,000	D	\$ 38.47	41,562	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	200	D	\$ 38.475	41,362	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	600	D	\$ 38.48	40,762	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	1,300	D	\$ 38.49	39,462	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	200	D	\$ 38.5	39,262	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	300	D	\$ 38.51	38,962	D
	05/30/2008 ⁽²⁾	05/30/2008	S	100	D	\$ 38.52	38,862	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	500	D	\$ 38.53	38,362	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	228	D	\$ 38.54	38,134	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	100	D	\$ 38.555	38,034	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	100	D	\$ 38.594	37,934	D
Common Stock	05/30/2008 ⁽²⁾	05/30/2008	S	400	D	\$ 38.6	37,534	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 22	05/30/2008 ⁽²⁾	05/30/2008	M	11,528	11/09/2000	05/08/2010 ⁽³⁾	Common Stock	11,528

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BAFFI ROBERT C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			SVP, Technical Operations	

Signatures

G. Eric Davis,
Attorney-in-Fact

06/03/2008

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Transaction made pursuant to the Employee Stock Purchase Plan.
- (2) Transaction made pursuant to a Rule 10b5-1 Trading Plan executed February 29, 2008.
- (3) Original option grant vested 6/48ths on 11/9/2000 and 1/48th on the 9th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.